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Premonitory-like Symptomatology  
in Migraine
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I t has been historically accepted that migraine involves symptomatology outside of head pain. These symptoms can be as equally disabling as the pain, and can include tiredness, concentration impairment, memory impairment and mood change. The symptoms may start before the onset of pain and can persist throughout the headache phase, and even after effective headache treatment into the 
postdrome. Despite knowledge of these symptoms, their neurobiologic basis and relationship to migraine pain is poorly understood. The fact 
that these symptoms start early, up to hours to days before the onset of headache, and are so symptomatically heterogeneous, suggests 
that the neurobiology of migraine extends beyond conventionally accepted anatomical pain areas within the brain – what has been known 
as the pain matrix or network. In a research area where no effective acute abortive drugs have gained a license for migraine since the 
triptans (serotonin 5-HT1B/1D receptor agonists), in the 1990s, further understanding of such symptomatology will allow therapeutic advances 
for treatments that may work before the onset of migraine pain and thus prevent it. This review will outline our current understanding about 
the phenotype and neurobiology of the premonitory (prodromal) symptoms, which for the purpose of this review will be called ‘premonitory-
like’, given they can start before or during pain. Symptoms starting after pain resolution (postdromal symptoms) will not be covered here.
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It has been recognised for centuries that symptoms outside of pain are reported with 
migraine.1 Symptoms prior to the onset of migraine headache have been called premonitory or 
prodromal symptoms and the symptoms after headache resolution have been called postdromal 
or resolution symptoms in the literature.2–4 These symptoms are likely to be a continuum, 
starting before the onset of headache, and persisting throughout the headache phase, perhaps 
becoming less noticeable in the presence of moderate-to-severe pain. They can also persist after 
the resolution of pain before return to normal function, and studies have shown similarities in 
the phenotype of premonitory and postdromal symptoms.5
These non-painful cognitive, homeostatic and sensory sensitivity symptoms can be disabling and 
prevent normal function, adding to the morbidity associated with a migraine attack. It is therefore 
important to recognise their phenotype and relationship to headache, and further to understand their 
neurobiology. Most research in this field has focused on symptoms displayed before the onset of 
moderate–severe migraine headache. However, for the purpose of this review we call the symptoms 
‘premonitory-like’ as we have observed that they can start at the same time as pain, or occur during 
the pain itself. Whether symptoms start before or during pain, they are likely to be biologically 
mediated the same way, regardless of their onset within the migraine timeline; hence the use of this 
definition here. For the purpose of this review, premonitory-like symptoms will be defined as any non-
painful symptom associated with the migraine attack, possibly predictive of impending headache 
and starting before the onset of pain, or non-migraine-defining symptoms occurring during the pain 
itself. Postdrome or resolution symptoms are neurobiologically poorly understood at the moment, 
and phenotypically not well reported in the literature and will therefore not be included in this review.
It should also be noted that premonitory-like symptoms are often mistaken as migraine triggers; 
for example, a craving for chocolate may be a premonitory symptom, but patients are likely to 
interpret this as chocolate often triggering a migraine headache in them.6 Increasingly, the evidence 
suggests that many of the triggers reported by patients are not reproducible in experimental 
research, and may actually represent the manifestation of premonitory-like symptomatology.6,7 
Therefore, there is an increasing need to understand the mediation of such symptoms, and their 
differentiation from migraine triggers, to allow patients to understand their condition better and 
effectively manage their lifestyles accordingly.
Prevalence of premonitory-like symptoms in migraine
The true prevalence of premonitory symptoms among migraineurs is unknown, as most of the studies 
are retrospective and the numbers reported vary greatly across different studies.8–13 In addition, 
the majority of the studies performed so far have only looked at symptoms starting before the 
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onset of headache, the true definition of ‘premonitory symptoms’, rather 
than looking at the development of such symptoms with or during the 
onset of pain. Various retrospective studies in the literature have quoted 
prevalence rates of 9–88%.3,8–18 See Table 1 for a breakdown of studies to 
date in the literature looking at premonitory symptom prevalence.
Regardless of the prevalence, Giffin et al.16 showed with an electronic 
diary study that the experience of these symptoms is highly predictive 
of impending migraine headache. In this study patients were reliably 
able to predict the onset of headache 72% of the time, after reporting 
premonitory symptomatology.16 Symptoms have been reported up 
to 72 hours prior to the onset of pain previously, but the Giffin et al.16 
study showed that symptoms occurring within 6 hours of the onset 
of headache had the highest predictive value, and most symptoms 
occurred within 24 hours of headache onset.
Two studies have also shown the existence of such symptoms among 
children and adolescents, even as young as 18 months.17,18 One of 
these showed a prevalence of 67% in the cohort of 103 children and 
adolescents with migraine.18 The other study preselected patients who 
had reported at least one premonitory symptom.17
These studies highlight consistently the presence of these symptoms 
among migraineurs and their ability to predict impending headache, as well 
as their presence or development at any time during a migraine attack. 
These features suggest that the symptoms may not be directly pain-related 
or mediated by pain, and are likely mediated by additional brain structures 
outside of the well-recognised trigeminovascular pain pathway.
Phenotype of premonitory-like symptoms
Despite the varying population types used in the studies performed 
to date, as well as varying methods of data collection, such as patient 
interview, self-administered questionnaires or electronic diaries, and 
whether data were collected from the headache clinic or wider population, 
the phenotype of symptoms reported in adults is largely consistent across 
these studies (see Table 1).9–16 The most common symptoms seem to be 
fatigue (see red in Table 1), mood change (see blue in Table 1) and yawning 
(see green in Table 1). These are consistent across the studies. Other 
common symptoms are neck stiffness and concentration difficulty.
The most commonly reported symptoms group largely into cognitive- 
or sleep-related symptoms (mood change, concentration or memory 
impairment, yawning, sleep disturbance and fatigue), migraine-like 
symptoms and sensory sensitivities (photophobia, phonophobia, nausea, 
mild head or eye discomfort and neck stiffness) and other homeostatic 
symptoms such as frequency of micturition, food cravings and bowel 
habit change. Paediatric studies have shown that the phenotype in 
children and adolescents is mostly comparable to that in adults.17,18
Relationship of symptoms to the neurobiology  
of migraine
The role of the brainstem as the driver for migraine attacks has been 
increasingly accepted.19 Various imaging studies in humans have 
now shown activity in brainstem structures during acute pain.20–24 
Premonitory-like symptomatology clearly involves brain areas outside 
of pain pathways, given the variable phenotype of symptoms produced. 
The broad groups of symptoms that most of the symptoms reported 
by patients fall into could help us understand the biologic basis of the 
symptoms, by considering involvement of the limbic system (emotional 
change, tiredness and concentration impairment),25 dopaminergic 
pathways (yawning),26 the hypothalamus (neck discomfort, sleep 
disturbance, thirst, cravings, frequency of micturition)27,28 and other 
brainstem areas (nucleus of tractus solitarius and nausea).29
Such theories alluding to the wider neurobiology of migraine led to the first 
functional brain imaging studies during the premonitory stage of migraine 
Table 1: A summary of studies performed looking into premonitory symptomatology in migraine
Study Design and recruitment n Patients selected Most common premonitory symptoms 
reported
Prevalence if available (of at 
least one or more symptom)
Blau3 (1980) Retrospective oral questioning (clinic) 50 Adults and children 
(minimum age 12)
Yawning, tiredness, mood change 34%
Drummond and 
Lance8 (1984)
Retrospective oral questioning (clinic) 530 Adults Mood change, appetite change, changes 
in alertness 
30%
Amery et al.9 (1986) Retrospective questionnaire 
(population)
149 Adults Low energy, pallor, photophobia, 
phonophobia
Preselected as having 
premonitory symptoms
Waelkens12 (1985) Prospective questionnaire (clinic) 49 Adults Irritability, depression, fatigue, hunger, 
bulimia, yawning
88%
Russell et al.10 
(1996)
Retrospective face-to-face/telephone 
interview (clinic)
484 Adults Hyperactivity, depression, altered eating 
habits, irritability, yawning
9%
Rasmussen et al.11 
(1992)
Retrospective interview and 
questionnaire (population)
1,000 Adults Depression, tiredness, hyperactivity 14%
Kelman14 (2004) Retrospective interview (clinic) 893 Adults Tiredness, malaise, fatigue, mood change 30%
Giffin et al.16 (2003) Prospective, electronic diary (clinic) 97 Adults Tiredness, concentration difficulty,  
stiff neck
Preselected as having 
premonitory symptoms
Schoonman et al.13 
(2006)
Retrospective questionnaire (clinic) 461 Adults Fatigue, phonophobia, yawning 87%
Quintela et al.15 
(2006)
Retrospective questionnaire  
(GP surgery)
100 Adults Anxiety, phonophobia, irritability,  
low mood, yawning
84%
Cuvellier et al.18 
(2009)
Retrospective questionnaire (clinic) 103 Children and 
adolescents
Face change, fatigue, irritability 67%
Karsan et al.17 
(2016)
Retrospective, analysis of clinic letters 
(clinic)
100 Children and 
adolescents
Fatigue, mood change, neck stiffness, 
yawning
Preselected as having 
premonitory symptoms
The most common premonitory symptoms are colour-coded: fatigue (red), mood change (blue) and yawning (green).
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in 2014.29–31 These provided supportive evidence for the early involvement 
of the dorsal pons, hypothalamus and various cortical areas in migraine 
attacks, and interestingly revealed early involvement of the brainstem 
before the onset of pain. These findings confirmed the suspected 
brain regions hypothesised as being involved in mediating some of the 
symptoms reported by patients, including an area in the brainstem which 
seemed likely to be the nucleus of the tractus solitarius mediating nausea.29
The occurrence of premonitory symptoms, their ability to predict an 
impending headache and the anatomical structures alluded to in imaging 
studies during premonitory symptoms, suggest that they could provide 
vital neurobiologic information about the basis of a migraine attack, and 
important clues about therapeutic development in the future. If we can 
understand the neurotransmitter systems at play early before the onset 
of pain, we may be able to understand how to develop targeted therapies 
that work on these systems and may be able to prevent pain onset at all. 
Small studies of this type have been performed using domperidone, taken 
during premonitory symptoms, acting on the dopamine pathway,32,33 and 
have shown promising results, but larger randomised placebo-controlled 
trials are warranted.
In addition, triggering studies as a way of modelling human migraine have 
also increased knowledge in this area. Nitroglycerin (NTG) and pituitary 
adenylate-cyclase activating protein (PACAP) have been shown to be 
able to trigger premonitory symptoms in migraineurs, similar to those 
experienced with spontaneous attacks.34,35 NTG is a well-established 
migraine-triggering model in the literature,36 but it has not been used 
extensively yet to study premonitory-like symptomatology. PACAP is newer 
in migraine research37 and its ability to trigger migraine38 has led to interest 
in agents targeted against the PAC1 receptor as a possible treatment 
for migraine.39 In a similar way, the human triggering models may, in the 
future, allow us to explore newer effective triggering compounds and 
thereby further study antagonising the exogenous trigger molecules, in 
the hope of being able to prevent premonitory symptom and pain onset.
Conclusions
Migraine is a disorder of more than head pain, and comprises 
heterogeneous non-painful symptomatology that can be equally 
debilitating, and contribute to the morbidity of the attack. These non-
painful symptoms may start hours to days before the onset of pain, or 
start alongside the pain, and may persist after headache resolution. It is 
likely from observation of our patients in the clinic that these symptoms 
are probably under-reported. This is partly due to failure of patient 
recognition unless asked, and due to physicians not asking about specific 
symptoms that patients may not themselves have associated with a 
headache attack, or may have associated with trigger factors rather 
than premonitory-like symptoms. Recognition of the presence of these 
symptoms, particularly before the onset of headache, and differentiation 
of them from true migraine triggers, can help patients understand the 
wider impact of the attack, and reliably predict the onset of impending 
headache, as well as allow early and effective headache management. 
Education about these symptoms, and helping patients understand that 
these are explained as being part of the migraine attack, can increase 
understanding of the symptoms, and limit unnecessary misinterpretation 
of some of these symptoms as migraine triggers and therefore limit 
unhelpful lifestyle modifications. In addition, in the paediatric population, 
education about the recognition of these symptoms among parents, 
teachers and carers, can allow prompt treatment in this population who 
may not always be able to display or vocalise pain. From a research 
perspective further understanding of the neurobiologic basis of these 
symptoms, through functional imaging and through pre-clinical models, 
will help us understand the regions of the brain likely to be involved, and 
thereby help with planning future therapeutic clinical trials.
In addition, increasingly studying the symptoms in humans through 
triggering models, imaging studies and treatment in randomised-
controlled trials may help us identify future therapeutic targets. 
Identification of specific neurotransmitter systems in certain brain 
regions could help development of targeted migraine therapies, in an 
exciting era when migraine therapeutics has evolved greatly, but there 
will always be a need for more targeted acute and preventive therapies 
to help those affected by this disabling disorder with greater efficacy 
and limited side-effect profiles. Future clinical trials should assess 
efficacy of the drugs in question in treating associated non-headache 
symptomatology in migraine, as well as headache, as this can be equally 
debilitating and impair the quality of life of those affected. 
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